NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2031210313

Registered date:14/09/2021

Phase 2 study of Trastuzumab Deruxtecan in the neoadjuvant treatment for patients with HER2 positive gastric and gastroesophageal junction adenocarcinoma

Basic Information

Recruitment status Recruiting
Health condition(s) or Problem(s) studiedHER2 positive gastric and gastroesophageal junction adenocarcinoma
Date of first enrollment14/09/2021
Target sample size37
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Trastuzumab Deruxtecan (T-DXd) will be administered at a dose of 6.4 mg/kg (decimal) by intravenous infusion every 21 days (3 weeks)

Outcome(s)

Primary OutcomeMajor pathological response [MPR] rate: by central assessment
Secondary Outcome1. MPR rate determined by the local assessment 2. Pathological complete response (pCR) rate 3. Curative Resection Rate 4. AE rate 5. Biomarkers in the Primary cohort and the Exploration cohort 6. MPR rate determined by investigator assessment in the Exploration cohort 7. pCR rate determined by investigator assessment in the Exploration cohort 8. Curative Resection Rate in the Exploration cohort 9. AE rate in the Exploration cohort

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria1. Histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction. 2. Has HER2 overexpression (IHC3+, or IHC2+ and ISH positive [FISH or DISH]). (HER2 Low expression: IHC1+, or IHC2+ and ISH-negative [FISH or DISH] with HER2-ECD > 11.6 ng/mL in the exploratory cohort). 3. Have previously untreated gastric and gastroesophageal junction adenocarcinoma and cT2-4 and/or cN+M0.according to the UICC TNM classification (8th edition), 4. Age >= 20 years as the day of informed consent. 5. Has an ECOG performance status (PS) of 0 or 1. 6. Has a left ventricular ejection fraction (LVEF) >= 50% by either echocardiogram (ECHO) or multigated collecting acquisition (MUGA) scan within 28 days before enrollment (acceptable on the same day of the week). 7. Has a corrected QT interval (QTc) <= 470 ms in females, or QTc <= 450 ms in males based on a 12-lead ECG screening within 28 days before enrollment (allowed on the same day of the week). [Fridericia's correction is recommended] 8. Satisfies all of the following requirements within 14 days before enrollment (allowed on the same day of the week). -Absolute neutrophil count >=1500 / mm3 [except for assessment <= 14 days after administration of Granules colony-stimulating factors (G-CSF)] -Hemoglobin >= 8.0 g/dL (except for those measured within 7 days after whole blood transfusion or packed red blood cells) -Platelet count >=100000 per mm3 (excluding measurements within 7 days after platelet transfusion). -Total bilirubin <=1.5 mg/dL (patients with gilbert's syndrome will be allowed if they have < 3.0 mg/dL). -AST(GOT)<=100 IU/L -ALT(GPT)<=100 IU/L -Serum albumin >= 2.5 g/dL -Calculated creatinine clearance (Cockcroft-Gault *) or the actual value >= 30 mL/min * Cockcroft-Gault equation: creatinine clearance= (140 - age) * body weight (kg) / (72 * Serum creatinine) (* 0.85 x the value obtained for females). -PT(INR)< 1.8 -aPTT < 60 seconds 9. Has a treatment-free period from the end of pre-treatment to before enrollment (allowed on the same day of the week), defined as: i. Surgery with general anesthesia : >= 4 weeks ii. Radiotherapy: >= 4 weeks (including palliative stereotactic body radiation therapy to the chest; palliative stereotactic body radiation therapy to other than the chest >= 2 weeks; abdominal vertebral bodies should be included in the abdomen). iii. Chloroquine and hydroxychloroquine : >= 15 days 10. Has a prior radiotherapy or surgical AE recovered of <= Grade 1 or <= baseline on CTCAE v5.0. However, this shall not apply to events where the symptoms are stable even if they are grade 2 or higher. 11. Female of childbearing potential have a negative pregnancy test within 7 days before enrollment (allowed on the same day of the week). Male and Female of childbearing potential agree to contraception for a period (4 months for male and 7 months for Female) from informed consent to the last dose of study drug (see 4.3 "Pregnancy and contraception"). 12. Written informed consent of participation in the study has been obtained from the patient.
Exclude criteria1.Has a medical history/complication of myocardial infarction or congestive heart failure (New York Heart Association Classes II-IV) within 6 months before enrollment, corresponding to the value diagnosed as myocardial infarction as defined by the *manufacturer within 28 days before enrollment (allowed on the same day), unstable angina, or any serious arrhythmia requiring treatment. *: Manufacturer refers to a testing company used by a study implementation institution. **: Enrollment is allowed if a subject exceeds ULN, if the subject is examined and myocardial infarction can be excluded. 2.Active multiple cancers [Synchronous duplicate cancers and metachronous multiple cancers within 3 years prior to enrollment, but carcinoma in situ or other lesions corresponding to mucosal carcinoma that are considered curable with Local treatment will not be included in active multiple cancers.] 3.Has serious (hospitalized) complications (intestinal palsy, intestinal obstruction, pulmonary fibrosis, diabetes mellitus that is difficult to control, heart failure, myocardial infarction, unstable angina, renal failure, liver failure, psychiatric disorders, cerebrovascular disorders, etc.). 4.Has history of gastrointestinal perforation and/or gastrointestinal fistula within 6 months before enrollment. 5.Has any of the following infections: -HBs antigen positive -HBs antibody or HBc antibody and HBV-DNA positive -Active hepatitis C (eg, if HCV RNA is detected qualitatively) Patients who are HBsAg positive but who have achieved HBV DNA level < 1.3 log IU/mL (2.1 log copies/mL) after treatment with antiviral drugs such as NAs, are eligible for the study. 6.HIV infection has been documented. 7.Lung diseases are defined as: -Has a history of non-infectious interstitial lung disease or pneumonitis that required treatment, has interstitial lung disease or pneumonitis, or these lung diseases cannot be ruled out by radiographic examination before enrollment. -Severe pulmonary impairment (eg, pulmonary embolism within 3 months prior to enrollment, serious bronchial asthma, severe COPD, restrictive pulmonary disease, or pleural effusion). Lung-related autoimmune or connective tissue or inflammatory diseases (eg, rheumatoid arthritis, Sjogren's syndrome, or sarcoidosis) with clinically severe pulmonary risks. Has history of pneumonectomy. 8.Has history of concomitant autoimmune disease or chronic or recurrent autoimmune disease. 9.Administration of systemic adrenocortical hormones (except prophylactic administration for tests or allergic reactions, and temporary use for the purpose of reducing edema associated with radiotherapy) or immunosuppressants is required, or has received these treatments within 14 days before enrollment in the study. 10.Has unhealed wounds, ulcers, or fractures. 11.If patients are a pregnancy or breastfeeding patient. 12.Has documented severe hypersensitivity to study drug active ingredients or additives. 13.Has history/complications of severe hypersensitivity reactions to other monoclonal antibodies. 14.If you have uncontrolled acute systemic infection that requires Infusion intravenous antibiotic, antiviral, or antifungal drug. 15.Unwilling or unable to comply with any of implementation matters stipulated in the study implementation protocol or any of the instructions of the physician. 16.The investigator or subinvestigator considered it ineligible for the study.

Related Information

Contact

Public contact
Name T-DXd_NAC clinical trial coordinating committee Secretariat
Address 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan Chiba Japan 277-8577
Telephone +81-4-7133-1111
E-mail T-DXd_NAC_core@east.ncc.go.jp
Affiliation National Cancer Center Hospital East
Scientific contact
Name Kohei Shitara
Address 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan Chiba Japan 277-8577
Telephone +81-4-7133-1111
E-mail T-DXd_NAC_core@east.ncc.go.jp
Affiliation National Cancer Center Hospital East